[Irradiation for prevention of gynecomastia prior to estrogen therapy in cases of carcinoma of the prostate (author's transl)].
The most frequent and most unpleasant side-effect of therapy with estrogen hormones in patients with carcinoma of the prostate is the painful gynecomastia. Since 1969, we have been performing the prophylactic irradiation of the mammary glands on 284 patients in order to prevent a hormone-induced gynecomastia. The majority (262 patients) was irradiated with 600 rad surface dose in fractions of 150 rad prior to the hormone therapy. One hundred and two patients, having been treated endocrinologically for 2-75 months, had a follow-up examination. After irradiation, only 19% of the patients did not develop a gynecomastia, and 60% had no mamillary hyperesthesias. Compared to other authors, the therapy was less efficient, the symptoms, however, were discrete. As a consequence, an increase of the radiation dose as well as an alteration of the fractionation must be used.
D000368:Aged; D001940:Breast / Q000254:growth & development / Q000528:radiation effects; D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006177:Gynecomastia / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010146:Pain; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011879:Radiotherapy Dosage
D004967:Estrogens
Bestrahlung zur Gynäkomastie-Prophylaxe vor der Oestrogen-Therapie beim Prostata-Carcinom